

1 **Title**

2 Single-cell Herpes Simplex Virus type-1 infection of neurons using drop-based
3 microfluidics reveals heterogeneous replication kinetics

4 **Authors**

5 Jacob P. Fredrikson^{1,2}, Luke F. Domanico³, Shawna L. Pratt^{1,2}, Emma K. Loveday^{1,2},
6 Matthew P. Taylor^{*3}, and Connie B. Chang^{*1,2,4}

7 **Affiliations**

9 ¹Department of Chemical & Biological Engineering, Montana State University, P.O. Box 173920,
10 Bozeman, MT 59717, USA

11 ²Center for Biofilm Engineering, Montana State University, 366 Barnard Hall, Bozeman, MT
12 59717, USA

13 ³Department of Microbiology & Cell Biology, Montana State University, P.O. Box 173520,
14 Bozeman, MT 59717, USA

15 ⁴Department of Physiology & Biomedical Engineering, Mayo Clinic, 200 First St. SW, Rochester,
16 MN 55905, USA

18 ***To whom correspondence should be addressed.**

19 **Email:** chang.connie@mayo.edu

20 mptaylor@montana.edu

22 **Abstract**

23 Single-cell analyses of viral infections often reveal heterogeneity that is not detected by
24 traditional population-level studies. This study applies drop-based microfluidics to investigate the
25 dynamics of HSV-1 infection of neurons at the single-cell level. We used micron-scale Matrigel
26 beads, termed microgels, to culture individual murine Superior Cervical ganglia (SCG) neurons or
27 epithelial cells. Microgel-cultured cells are subsequently enclosed in individual media-in-oil
28 droplets with a dual fluorescent-reporter HSV-1, enabling real-time observation of viral gene
29 expression and replication. Infection within drops revealed that the kinetics of initial viral gene
30 expression and replication were dependent on the inoculating dose. Notably, increasing
31 inoculating doses led to earlier onset of viral gene expression and more frequent productive viral
32 replication. These observations provide crucial insights into the complexity of HSV-1 infection in
33 neurons and emphasize the importance of studying single-cell outcomes of viral infection. The
34 innovative techniques presented here for cell culture and infection in drops provide a foundation
35 for future virology and neurobiology investigations.

36 **MAIN TEXT**

39 **Introduction**

40 Single-cell analyses have advanced our understanding of cellular physiology and viral
41 infection by facilitating the observation of underrepresented phenotypes. Viral infection studies
42 traditionally rely on population-level approaches where cells are cultured and infected in well
43 plates (1). However, these approaches often overlook the heterogeneous dynamics of infection
44 obscured by productive viral replication (1–5). Single-cell methods for both culture and infection
45 provide increased insights into infectious virus production, viral replication kinetics, and genetic
46 variability (4–11).

47 Herpes Simplex virus type 1 (HSV-1) is a ubiquitous pathogen which infects neurons to
48 establish lifelong persistent and recurrent disease (12, 13). The replication, persistence, and
49 transmission of HSV-1 are determined by the regulation and temporal expression of viral genes
50 (14, 15). Single-cell studies of HSV-1 infection in epithelial cells have revealed variability in the
51 dynamics of viral replication (2, 16, 17). Additionally, single-cell transcriptional analysis of HSV-
52 1 infected epithelial cells observed a highly variable abundance of viral transcripts temporally
53 classified as immediate-early, early, and late genes. While our understanding of epithelial cell
54 infection at the single-cell level is improving, single-cell neuronal cell infection studies have not
55 yet been achieved to date.

56 A powerful technique for studying single-cell viral infection is drop-based microfluidics
57 (1, 3, 18, 19). This method generates emulsions containing monodisperse, picoliter-sized, aqueous
58 drops suspended in oil that can be used in various single-cell assays. Drop-based microfluidic
59 methods facilitate the encapsulation of millions of single cells, enabling in-depth, high-throughput
60 analysis of viral and cellular heterogeneity (1, 3, 18). However, these methods have previously
61 focused on infections in non-adherent cells (18) that were suspended in aqueous drops (20–26).
62 Neurons require a soft, viscoelastic solid substrate that supports neurite development and growth,
63 which is not compatible with the aqueous environment produced using drop-based microfluidics
64 (27). Extending drop-based capabilities for adherent cultures at the single cell level would greatly
65 facilitate understanding of viral infection in physiologically relevant cells. Support for the growth
66 and development of cells which require solid substrates can be achieved with microscale hydrogel
67 beads, referred to as microgels (28, 29). Microgels provide a homogenous and highly tunable
68 biomimetic growth environment and have been previously used to culture multiple cell types such
69 as neurospheres, embryonic stem cells, and induced pluripotent stem cell aggregates (28, 29).
70 While microgels can offer a foundation for neuronal growth and maturation, their application in
71 drop-based methodologies for viral infections has never been assessed. Therefore, the
72 development of innovative techniques for individual neuron culture would facilitate single-cell
73 studies of HSV-1 infection.

74 In our study, we employ drop-based microfluidics to culture and perform live-cell tracking
75 of HSV-1 across different cell types susceptible to HSV-1 infection, including individual murine
76 Superior Cervical Ganglia (SCG) neurons and Vero cells. The single cells are embedded in
77 Matrigel microgels and subsequently encapsulated in drops containing defined inoculating doses
78 of HSV-1. HSV-1 infection is visualized using a recombinant fluorescent-protein expressing
79 reporter virus. Our results demonstrate that cells cultured within microgels are not accessible to
80 infection, whereas cells located on the microgel surface support a greater extent of infection
81 compared to suspension cells. Additionally, the onset of viral gene expression and replication
82 kinetics were monitored, revealing that higher inoculating doses result in an earlier onset and
83 progression of viral replication. In conclusion, these findings demonstrate that microgels provide
84 a solid surface that supports neuronal growth and development, enabling productive single-cell
85 HSV-1 infection within drops. The use of microgels for high-throughput single-cell culturing can
86 provide a valuable tool for future research in neurobiology and virology studies, further
87 enhancing our understanding of factors that affect viral replication dynamics.

88

89 Results

90 We developed drop-based microfluidic approaches to investigate the dynamics of HSV-1
91 infection in individual primary neurons (Figure 1). First, individual murine embryonic SCG
92 neurons are suspended in a Matrigel precursor solution that is processed into microgels with
93 diameters of approximately 100 μm using a microfluidic device (Figure 1A). The microgel-
94 cultured neurons are cultured for one week to allow for the growth and development of neurite
95 extensions. Subsequently, neurons are infected using a co-flow inoculation device, where

96 hydrogels and virus are simultaneously emulsified into drops. Co-flow inoculation allows precise
97 control of the viral inoculating dose to achieve single-cell infection (Figure 1B). To visualize
98 infection dynamics and replication kinetics, cells were infected with a dual fluorescent protein
99 (FP) expressing reporter HSV-1. This dual-reporter HSV-1 expresses YFP driven by an
100 immediate-early hCMV promoter and a mCherry-VP26 fusion driven by a late promoter (30).
101 Detection of virus expressed YFP reports the onset of viral gene expression upon infection, while
102 the detection of mCherry (RFP) corresponds to late viral gene expression and virion assembly
103 (Figure 1C). To observe infection dynamics at the single-cell level, we immobilized drops on a
104 ‘DropSOAC’ microfluidic device that enables incubation and fluorescence microscopy over the
105 course of infection (Figure 1D) (31, 32). The DropSOAC allows us to monitor and analyze the
106 progression of HSV-1 infection in individual neurons over time.

107 **Single-Cell Infection Outcomes of Vero Cells with Dual Reporter HSV-1**

108 To investigate the interactions between cells, microgels, and viral inoculum, we first conducted a
109 study focusing on HSV-1 infection of Vero cells and microgels. Vero cells are an epithelial cell
110 line commonly used for studying HSV-1 infections *in vitro* (12). We first evaluated whether the
111 location of the cell in the microgel alters the likelihood of a cell becoming infected. Vero cells
112 were either grown ‘in-microgels’, ‘on-microgels’, or placed ‘in-suspension’ before being
113 inoculated at 10 plaque forming units (pfu) per drop using a co-flow microfluidic device (Figure
114 2A). YFP detection was used to evaluate the percentage of infected cells (30). For the in-microgel
115 condition, Vero cells were first embedded within 100 μ m microgels before emulsification with
116 viral inoculum in drops. In-microgel infections produce only $1.7 \pm 1.4\%$ YFP positive detection at
117 16 hours post infection (hpi) (Figure 2B, 2C, 2F). The location of the cell in the microgel is a
118 random event from the drop-making process, with a low percentage of cells located on the
119 periphery of the microgel. No cells enclosed within the microgel expressed YFP (Figure 2B).
120 Interestingly, the cells that did express YFP were all found at the edge of the microgel (Figure
121 2C). For the on-microgel condition, Vero cells were seeded onto prefabricated microgels and
122 allowed to adhere for 4 hours prior to inoculation in drops. On-microgel infections produce $76.8 \pm$
123 5.0% YFP positive detection at 16 hpi (Figure 2D, 2F). For the in-suspension condition, Vero
124 cells were emulsified in drops suspended in media with viral inoculum. In-suspension infections
125 produce $50.0 \pm 3.7\%$ YFP positive detection at 16 hpi (Figure 2E, 2F).

126 Once we determined that Vero cell cells grown on microgels were the most susceptible to
127 infection, we further evaluated the effect of infectious dose with the co-flow inoculation system.
128 Cells on microgels were inoculated with doses ranging from 1, 10, and 100 pfu/drop. As
129 inoculating dose increased, the percentage of YFP positive cells increased from $45.2 \pm 4.1\%$ at 1
130 pfu/drop to $76.8 \pm 5.0\%$ at 10 pfu/drop and $95.2 \pm 2.2\%$ at 100 pfu/drop (Figure 2G). The extent
131 of YFP positive cells with increasing inoculating dose was statistically significant (one-way
132 ANOVA, $p = 1.3 \times 10^{-5}$, $df = 8$). This observation is consistent with the expectation that increasing
133 inoculating dose leads to greater extents of infection (33).

134 We hypothesized that the low number of Vero cells embedded in microgels with
135 detectable YFP is due to the inability of virions to penetrate Matrigel (34, 35). While Matrigel is a
136 porous material, the pore size is approximately 150 nm, nearly the same size as the 150-250 nm
137 diameter HSV-1 virion (36). To test our hypothesis that virion diffusion through Matrigel is
138 limited, the interaction between mCherry-VP26 labeled virions and Matrigel was observed on a
139 confocal microscope. Matrigel was pipetted onto glass and allowed to gel into a disc prior to the
140 addition of mCherry-VP26 labeled virions and subsequent imaging. Over 1.5 h, we observed no
141 HSV-1 virions diffuse past the interface of a Matrigel disc (Figure 3). Additionally, we saw no
142 accumulation of virions at the interface, indicating that the HSV-1 particles were not adhering to
143 or penetrating the gel and becoming immobilized (Figure 3A). These data demonstrate that HSV-
144

145 1 virions likely do not diffuse through the Matrigel. To assess whether the lack of particle
146 diffusion is related to size, we also evaluated the diffusion of fluorescent nanoparticles with
147 average diameters of 160 nm. Like the fluorescent virions, fluorescent nanoparticles do not enter
148 the Matrigel, but do accumulate at the aqueous interface (Figure 3B). These observations suggest
149 that only cells which are located on the surface of Matrigel microgels are accessible to HSV-1
150 infection.

151 The initial evaluations of Vero cell infections demonstrate that microgels provide a scaffold that
152 can be used to culture and infect adherent cell lines in drop-based assays. In comparison to
153 embedded cells, Vero cells cultured on the microgel have increased accessibility to HSV-1
154 infection and yield the highest percentage of detected infection. Cells that were not located on the
155 surface of the microgels were unlikely to become infected with HSV-1 as the virions do not
156 diffuse through Matrigel. The reduced infection observed in suspended Vero cells is hypothesized
157 to be caused by changes to cellular permissiveness to HSV-1 infection.

158 **Growth of Individual SCG Neurons in Microgels**

159 We next employed our microgel culturing system for the *in vitro* growth and development of
160 individual primary mouse SCG neurons. Dissociated SCG neurons, unlike adherent epithelial
161 cells such as Vero cells, require structural support to promote neurite development both during
162 culture and microfluidic manipulation. Neurites, including axons and dendrites, are critical for
163 neuronal homeostasis, metabolic regulation, and synaptic signaling (27, 37). To foster neurite
164 development, SCG neurons were embedded in Matrigel microgels using a drop-based
165 microfluidic device. Subsequently, the neurons were cultured to allow maturation and neurite
166 extension over a period of seven days. After seven days in culture, the neuronal cell bodies
167 migrated to the peripheral regions of the microgels, and robust neurites were observed either
168 within the microgels or on their external curvature (Figure 4A). To confirm that the embedded
169 neurons reached physiological maturity, we performed immunofluorescence staining for
170 phosphorylated neuro-filament H (N-F), a protein localized in axons of mature neurons. SCG
171 neurons grown in Matrigel microgels exhibited visible N-F signal in neurite extensions (Figure
172 4B, red). These findings indicate that microgels provide a suitable growth environment for
173 individual neurons, enabling the production of neurite extensions and promoting maturation.

174 **Single-cell Infection of SCG Neurons**

175 We next investigated the capacity to infect individual mature SCG neurons within microgels
176 using dual reporter HSV-1. Microgel-cultured neurons were infected with different inoculating
177 doses of 1, 10, or 100 pfu per drop and imaged for YFP at 16 hpi. A representative image of YFP
178 expression in an infected neuron is shown in Figure 4D. At the lowest viral concentration of 1
179 pfu/drop, $37.3 \pm 6.3\%$ of SCG neurons exhibited detectable YFP (Figure 4C). SCG neurons
180 infected with 10 and 100 pfu/drop demonstrated significantly higher percentages of infection,
181 with 61.6 ± 2.5 and $72.2 \pm 6.6\%$ of YFP positive cells, respectively (Figure 4C). To determine the
182 relationship between inoculating dose and YFP positivity, we conducted a one-way ANOVA and
183 found that inoculating dose had a significant impact on YFP detection across 1, 10, and 100
184 pfu/drop inoculations ($p = 5.9 \times 10^{-4}$, $df = 8$). Our results demonstrate that primary SCG neurons
185 cultured in microgels and infected in microfluidic drops are susceptible to HSV-1 infection and
186 support viral gene expression, as reported by YFP detection.

187 **Timing and Outcomes of Viral Gene Expression in Individual SCG Neurons**

188 We next examined the kinetics of viral gene expression in single neurons by detecting
189 YFP for the onset of viral gene expression and RFP for late viral gene expression (30). To
190 monitor and quantify the timing of viral gene expression in single neurons infected with dual-
191 reporter HSV-1, mature microgel-cultured neurons were emulsified with viral inoculum and

192 placed in a microfluidic chamber called a DropSOAC (Figure 5A). The DropSOAC immobilizes
193 the drops and allows for temporal tracking and fluorescence quantification of individual cells
194 (31). Images of infected neurons were acquired every 15 minutes for 16 hours, with image
195 acquisition starting 1 hour after in-drop inoculation (Figure 5B, SI Movie 1). The onset of FP
196 detection was determined by the point at which the fluorescent pixel intensity surpassed the
197 background threshold value (Figure 5C).

198 To assess the impact of inoculating dose on the detection of HSV-1 expressed FPs in
199 single neurons, microgel-cultured neurons were infected with 1, 10, and 100 pfu/drop and imaged
200 for 16 hours. Neurons infected with 1 pfu/drop exhibited an onset of YFP detection at 4.9 ± 2.0
201 hpi (Figure 5D). Neurons infected with 10 pfu/drop exhibited an onset of YFP detection at 5.5 ± 2.8 hpi.
202 Neurons infected with 100 pfu/drop displayed the earliest onset of YFP detection at 3.3 ± 1.7 hpi.
203 Based on a one-way ANOVA, we found that the timing of YFP detection decreased with
204 increased inoculating dose ($p = 1.1 \times 10^{-7}$ $df = 166$), indicating that the inoculating dose
205 significantly affects the onset of HSV-1 gene expression in single neurons.

206 Neurons were further examined for RFP detection, which correlates with the progression
207 of viral replication. We observed that only 2.6 and 6.5% of YFP positive cells become RFP
208 positive at 1 and 10 pfu/drop, respectively (Figure 5D). However, neurons infected with 100
209 pfu/drop exhibited much higher rates of RFP positivity, with 55.7% of YFP positive cells
210 becoming RFP positive by 16 hpi (Figure 5D). The average timing of RFP detection in cells
211 infected with 100 pfu/drop was 9.4 ± 2.5 hpi (Figure 5D). No cells were detected that were RFP
212 positive and not YFP positive. These data demonstrate that in our single-neuron drop-based
213 culturing and infection system, we can observe dose-dependent progression of HSV-1 infection in
214 real-time.

215 From the time-lapse data, we estimated the progression of viral replication by calculating
216 the timing between YFP and RFP detection in each infected neuron. At 100 pfu/drop, we
217 observed an average time of 6.6 ± 2.2 hours between YFP and RFP detection (Figure 5E). To
218 determine if the timing of YFP detection influences the timing of RFP detection, we implemented
219 a linear regression model, which predicts that single neurons will become detectably RFP positive
220 6.6 ± 1.8 h after onset of YFP detection ($t_{RFP+} = 6.6(\pm 1.8) + 1.0(\pm 0.6)t_{YFP+}$, $p = 0.002$). However, the
221 correlation between the onset of YFP detection and conversion to YFP/RFP positive detection
222 was weak ($R^2 = 0.23$), indicative of the heterogenous infection in single neurons. Thus, we
223 conclude that the timing of YFP detection is not predictive of the timing of RFP detection.

224 We also monitored and quantified the timing of FP detection in Vero cells infected with
225 dual reporter HSV-1. Similar to our previous on-microgel condition, Vero cells were cultured on
226 microgels, then encapsulated with viral inoculum, and placed in a DropSOAC device. We
227 observed similar trends in single Vero cells to those observed in single neurons (Figure 6A). Vero
228 cells infected with 1 pfu/drop exhibited an onset of YFP detection at 6.6 ± 2.6 hpi. Vero cells
229 infected with 10 pfu/drop exhibited an onset of YFP detection at 5.0 ± 2.0 hpi. Vero cells infected
230 with 100 pfu/drop displayed the earliest onset of YFP detection, at 3.5 ± 1.5 hpi. Using a one-way
231 ANOVA, we found that the timing of YFP detection decreased with increasing inoculating doses
232 in single Vero cells ($p = 1.9 \times 10^{-35}$, $df = 649$) (Figure 6A).

233 In a similar trend to neuronal infection, 1.9 and 4.6% of YFP positive Vero cells became
234 RFP positive at 1 and 10 pfu/drop, while 64.2% of YFP positive Vero cells became RFP positive
235 at 100 pfu/drop (Figure 6A-C). From the time-lapse data, linear regression predicts that at 100
236 pfu/drop, Vero cells become detectably RFP positive 6.4 ± 1.0 h after onset of YFP detection;
237 however, the fit is weak (linear regression, $t_{RFP+} = 6.4(\pm 1.0) + 0.9(\pm 0.3)t_{YFP+}$, $p = 1.1 \times 10^{-7}$, $R^2 = 0.22$
238) (Figure 6B). The concordance of both the extent of RFP positive cells and the progression of

239 YFP-to-RFP detection suggests that inoculating dose, not cell type, plays an important role in
240 determining outcomes of HSV-1 infection.

241 In summary, we demonstrate the use of microfluidic methods for the culture and infection
242 of Vero cells and primary SCG neurons to observe progression of HSV-1 infection with single-
243 cell resolution. We find that inoculating dose influences the extent and frequency of progression
244 for HSV-1 infection in both cell types. Specifically, at higher inoculating doses, cells express
245 detectable YFP earlier and are more likely to progress to detectable RFP progression and viral
246 replication. These experiments validate the use of drop-based culturing and live-cell tracking of
247 HSV-1 across different cell types susceptible to HSV-1 infection.

248 **Discussion**

249 In this study, we utilized drop-based microfluidics for the culturing of individual cells and
250 the subsequent infection with HSV-1. Culturing cells using Matrigel microgels enabled both
251 neurons and adherent epithelial cells to maintain physiologically relevant morphologies.
252 Following the culturing of cells within these microgels, we implemented a co-flow inoculation
253 approach that allows for precise control over infection conditions. Subsequently, a specialized
254 microfluidic DropSOAC device (32) enabled the isolation of individually infected cells and real-
255 time observation of HSV-1 replication through detection of virally expressed FPs. Collectively,
256 these techniques offer innovative means to culture cells and observe real-time HSV-1 replication
257 kinetics at the single-cell level.

258 Neurons are the focal point of HSV-1 persistence, morbidity, and mortality; therefore, it is
259 important to understand how HSV-1 infection progresses in primary neurons (12). However,
260 primary neurons require a solid substrate that supports neurite development and growth, limiting
261 their usability in an aqueous drop environment. To produce a solid substrate for cells, we
262 embedded primary SCG neurons in Matrigel microgels, which promoted their maturation and
263 facilitated microfluidic manipulation. We observed that microgel-cultured SCG neurons grew
264 robust neurite extensions that follow the external curvature of the microgels. Additionally,
265 immunofluorescence imaging demonstrated the presence of phosphorylated-neurofilament H in
266 the neurite extensions, indicating SCG neuron maturation and axonal development, which was
267 achieved by 7 days in culture. The use of Matrigel provided not only the solid substrate, but also
268 laminin cofactors that are important for SCG survival and development (38, 39). This work shows
269 that Matrigel microgels provide the necessary growth factors and support for sustained growth
270 and viability of neurons in culture.

271 Microgels provide support for subsequent microfluidic manipulation of cultured neurons
272 for in-drop infection. We achieved $72.2 \pm 6.6\%$ infection of individual neurons grown in
273 microgels. Infections elicited a wide distribution of YFP detection onset in single neurons,
274 ranging from 1.25 - 16 hpi. The variability could be the result of HSV-1 entry at distal axon sites
275 leading to delays in replication. Yet, it is more likely the result of a heterogenous establishment of
276 infection, as a wide-distribution of YFP detection onset also occurred in Vero cells. Similarly, we
277 observed large differences in the time it takes a YFP positive cell to progress to RFP positivity in
278 both cell types. Based on these observations, we hypothesize that the establishment and
279 progression of HSV-1 infection is heterogeneous across individual neurons. This hypothesis is
280 supported by recent single-cell transcriptomic studies of HSV-1 infection in epithelial cells (2)
281 and neurons (16). Each study reported several hours of variation in the onset of viral gene
282 expression despite synchronous inoculation. Further analyses observed that infected cells exhibit
283 high cell-to-cell variability in late viral protein detection and abundance, suggesting that the
284 progression of HSV-1 infection may be variable in single cells (17). These studies conclude that
285 heterogeneity in HSV-1 infection is caused more by cell-to-cell variation in metabolic or
286 immunological states within the population of susceptible and permissive cells.

287 Our results suggest that inoculating dose can also play a critical role in determining the
288 productive outcome of infection. We observed that inoculating dose directly affects the kinetics of
289 viral gene expression and the likelihood of productive replication. Our co-flow inoculation system
290 enables precise manipulation of inoculating doses, mixed in drops with individual cells. We
291 observed that YFP became detectable earlier in all cells infected with higher inoculating doses.
292 Importantly, all RFP positive neurons were detectably YFP positive before 6 hpi, suggesting that
293 early viral transcription is more likely to elicit productive viral replication. The dose dependence
294 on viral gene expression and productive replication aligns with other work that observed dose-
295 dependent HSV-1 replication in human foreskin fibroblasts (40). Similarly, the effects of lower
296 inoculating dose leading to slower kinetics of expression and low rates of productive replication
297 have been observed during HSV-1 infection of other non-neuronal cells (33, 40). Notably, we
298 were able to observe single-cell infection of neurons for longer observation periods. This longer
299 observation window revealed a large population of 'stalled' infections. Further studies are
300 required to understand the stage of viral replication at which progression stalls and the cellular
301 factors that influence this outcome of infection.

302 To further understand the complexities of the microgel in-drop infection system, we
303 investigated the effects of the microgel, the susceptible cell, and viral inoculum. We hypothesized
304 that cells cultured within the microgel were inaccessible to infection, which is consistent with the
305 minimal infection observed at 10 pfu/drop for Vero cells. Particle diffusion experiments
306 demonstrate a lack of virion diffusion into the Matrigel. Therefore, cells cultured in-microgel are
307 limited in their spatial accessibility to HSV-1 infection. However, cells cultured on-microgel were
308 found to be accessible to HSV-1 and achieved a maximum of $95.2 \pm 2.2\%$ infection. The
309 accessibility of cells to infection may partially explain why only a maximum of 78% of neurons
310 express detectable YFP following our highest inoculating dose. The SCG neurons needed to be
311 first encapsulated within the microgel, after which cell bodies and neurites could migrate to the
312 gel surface. It is possible that some of the cells that did not express detectable YFP were
313 inaccessible to infection. Alternatively, it is possible that these FP negative cells were infected but
314 represent a population of neurons that suppressed all viral gene expression.

315 In conclusion, we are the first to demonstrate in-drop infection of single primary neurons
316 cultured using microgels. The speed and scale of these microfluidic methods hold the potential for
317 high-throughput culturing and assaying of single neurons. The microgels could also act as a
318 scaffold for in-drop differentiation and manipulation of other primary cells (28, 29). While many
319 approaches to droplet cell culture rely on suspension cells to study viral infection and replication
320 (3, 21, 24), we observed an approximate 52% increase in infection when cells were cultured on
321 microgels, compared to the same cells cultured in suspension. Finally, our drop-based single-cell
322 approach captures heterogeneous events within a population that would otherwise be missed by
323 bulk culturing (3). In conclusion, the use of microgels for high-throughput single-cell culturing
324 can provide a valuable tool for future research in neurobiology and virology studies, further
325 enhancing our understanding of factors that affect viral replication dynamics.

326 Materials and Methods

328 **Vero Cell Culture.** Vero cells purchased from (American Type Culture Collection, Manassas,
329 VA) were maintained and subcultured in Dulbecco's Modified Eagle's Medium (DMEM)
330 supplemented with 10% fetal bovine serum (v/v) and 1% penicillin/streptomycin in 5% CO₂ at 37
331 °C.

332 **Mouse Superior Cervical Ganglia Neuron Dissociation.** Mouse Superior Cervical Ganglia (SCG)
333 were excised from embryos at 14 days post gestation from pregnant C57Bl/6 mice. The protocol
334 for isolating SCGs is approved by the Institutional Animal Care and Use Committee at Montana
335 State University (protocol# 2022-52-IA). Briefly, isolated SCGs were washed with Hank's

336 Balanced Saline Solution (HBSS) and resuspended in 0.25 mg/mL trypsin (Gibco) in HBSS for
337 dissociation and incubated for 15 minutes in a 37 °C water bath. Trypsinized SCGs were
338 centrifuged and resuspended in 1 mg/mL trypsin inhibitor (Gibco) in HBSS, then incubated for 5
339 minutes in a 37 °C water bath. Next, SCGs were centrifuged and resuspended in complete
340 neurobasal (neurobasal media (Gibco), 1X B27 (Gibco), 60 ng/mL 2.5S NGF (Millipore Sigma)
341 and 1% penicillin/streptomycin + glutamate (Gibco)) and dissociated by trituration using a 5 mL
342 Pasteur pipette (41). Dissociated neurons were then cultured as described in complete neurobasal
343 media.

344 **Dual Reporter Herpes Simplex Virus-type 1.** Dual reporter HSV-1 was constructed, isolated, and
345 characterized as previously described (30). Vero cells were used for viral stock production and
346 plaque assay estimation of viral titers.

347 **Microfluidic Device Fabrication.** Negative master molds for the microfluidic devices were
348 prepared using standard photolithography techniques (42). Negative master molds were made
349 with Nano SU-8-100 photoresist (Microchem, Round Rock, TX, USA) on 3 silicon wafers
350 (University Wafer Inc., Boston, MA, USA University Wafer ID: 447). The microgel drop-maker
351 and the suspension cell co-flow inoculating device were fabricated to be 100 μ m tall. The co-flow
352 microgel inoculating drop-maker and the DropSOAC (31) chambers were fabricated to be 150 μ m
353 tall. Devices were treated with (tridecafluoro-1,1,2,2-tetrahydrooctyl) trichlorosilane (1% v/v)
354 (Gelest) in fluorinated oil HFE 7500 (3M, Saint Paul, MN, USA) and left for solvent evaporation
355 at 55 °C.

356 **Microgel Production and Cell Encapsulation/Seeding.** Matrigel microgels were produced through
357 drop-based microfluidics using previously established protocols (43). Briefly, liquid Matrigel at
358 4 °C and 1.5% w/w fluorosurfactant (008, RAN Biotechnologies, MA, US) in HFE 7500 were
359 loaded into luer lock syringes and injected into the 100 μ m drop-maker using syringe pumps. The
360 flow rates used were $Q_{\text{Matrigel}} = 100 \mu\text{L/h}$ and $Q_{\text{HFE}} = 900 \mu\text{L/h}$. All equipment and reagents were
361 refrigerated at 4 °C to prevent premature gelation of the Matrigel. Drops were collected in
362 microcentrifuge tubes and incubated at 37 °C for 35 min to gel the drops. The resulting microgels
363 were washed with equal volumes of 1H,1H,2H,2H-Perfluoro-octanal (PFO) - HFE 7500 (20%
364 v/v) and PBS to drops. The cleaned microgels were then collected in PBS.

365 In experiments where Vero cells or dissociated SCG neurons were encapsulated in
366 microgels, cells were suspended in the liquid Matrigel at 1×10^6 cells/mL prior to drop making.
367 After collecting the resulting microgels in PBS, they were placed in well plates with the
368 appropriate growth medium. Vero cells were maintained in DMEM - 10% FBS - 1%
369 penicillin/streptomycin in 5% CO₂ at 37 °C for 4 h before experimentation. SCG neurons were
370 grown in complete neurobasal media at 37 °C in a 5% CO₂ enriched atmosphere for 7 days prior
371 to experimentation to allow maturation and neurite growth. 24 h after encapsulation, SCGs were
372 supplemented with 1 μ M Cytosine- β -D arabinofuranoside (Sigma C6645), a compound cytotoxic
373 to mitotically active, non-neuronal cells. In experiments where Vero cells were seeded onto the
374 microgels, empty microgels were mixed with 1×10^6 cells per 1 mL_{Microgel} in a well plate. Cells
375 were allowed to adhere for 4 h prior to experimentation.

376 **Immunofluorescence Staining and Imaging.** After 7 days in culture, neurons grown in microgels
377 were collected in microcentrifuge tubes and washed with PBS. Cells were fixed with 1%
378 glutaraldehyde for 1 min and washed 3x with PBS. Cells were blocked with 2% BSA/PBS at
379 room temperature for 1 h and washed 3x with PBS. Cells were permeabilized with 0.1% Triton-X
380 / 0.125% BSA/PBS and washed 3x with 0.125% BSA/PBS. The primary antibody, anti-
381 Phosphorylated Neurofilament H (NF-H) (BioLegend), was added at 5 μ g/mL, incubated at room
382 temperature overnight, and then washed 3x in 0.125% BSA/PBS. The secondary antibody, Goat
383 anti-Mouse IgG (H+L), DyLight 550 (#84540 ThermoFisher), and Hoechst 33342 Solution

384 (ThermoFisher) were added at 5 μ g/mL and 20 μ g/mL respectively, for 1 h at 37 °C and then
385 washed 3 times with 0.125% BSA/PBS. Cells and microgels were loaded onto glass slides and
386 imaged on an epi-fluorescent microscope (Nikon Ti2). Cells were imaged in Phase
387 Contrast/DAPI/RFP.

388 In-Drop Infection Procedures. Cells were infected in drops. To infect cells seeded onto or cultured
389 in microgels, microgels were collected from well plates and pelleted by centrifuging the
390 microgels at 200 x g for 1 min. The pelleted microgels were loaded into luer lock syringes. HSV-
391 1 inoculum was diluted into the appropriate media. For Vero infections, HSV-1 stock was diluted
392 in DMEM - 10% FBS - 1% penicillin/streptomycin. For SCG infections, HSV-1 stock was diluted
393 in complete neurobasal media. HSV-1 was diluted at concentrations of 1.1×10^6 , 1.1×10^7 , and
394 1.1×10^8 pfu/mL, resulting in inoculating conditions of 1, 10, and 100 pfu/drop, respectively. The
395 virus solutions and a 1.5% solution of RAN in HFE were loaded into individual luer lock
396 syringes. The three syringes were loaded onto syringe pumps and injected into the appropriate
397 inlet channels of the microfluidic co-flow microgel inoculation device. Flow rates were $Q_{HFE} =$
398 $2500 \mu\text{L/h}$, and $Q_{\text{Matrigel}} = Q_{\text{Virus}} = 250 \mu\text{L/h}$. Drops were collected into microcentrifuge tubes and
399 either placed in an incubator at 37 °C for end-point imaging or injected into DropSOAC chambers
400 for time-lapse imaging.

401 To infect Vero cells suspended in media, Vero cells were removed from subculture using
402 Trypsin-EDTA and washed in PBS. Cells were suspended in DMEM - 10% FBS - 1%
403 penicillin/streptomycin at 1×10^6 cells/mL and loaded into a luer lock syringe. HSV-1 was diluted
404 into DMEM - 10% FBS - 1% penicillin/streptomycin at a concentration of 3.8×10^7 pfu/mL
405 resulting in an inoculating condition of 10 pfu/drop. The virus solution and a 1.5% solution of
406 RAN in HFE were loaded into individual luer lock syringes. The three syringes were loaded onto
407 syringe pumps and injected into the appropriate inlet channels of the co-flow suspension cell
408 inoculating drop-maker. Flow rates were $Q_{HFE} = 2000 \mu\text{L/h}$, and $Q_{\text{Cells}} = Q_{\text{Virus}} = 250 \mu\text{L/h}$. Drops
409 were collected into microcentrifuge tubes and placed in an incubator at 37 °C for endpoint
410 imaging.

411 End-Point Imaging of Inoculated Cells. To visualize in-drop infection, drops were loaded into
412 capillary tubes and imaged. Cells were imaged in phase contrast/FITC/TRITC. To quantify the
413 percentage of infected cells at 16 hpi, the drops containing infected cells were broken using 20%
414 v/v PFO-HFE. Breaking the emulsion allowed for easier visualization and quantification of cells.
415 The broken supernatant containing infected cells was pipetted onto a polytetrafluoroethylene
416 (PTFE) printed microscope slide and imaged.

417 Time-Lapse Imaging of Inoculated Cells. To track the progression of FP detection in single cells,
418 drops containing infected cells were loaded into DropSOAC devices with modified aluminum
419 capsules (31). The capsules were placed in a microscope stage top incubation chamber (OKOlab)
420 at 37°C. Images in Phase Contrast/YFP/RFP were taken every 15 min for 16 h. Tile scans of each
421 chamber were taken to capture as many cells as possible. Image acquisition began within 1 hr
422 post-inoculation.

423 HSV-1 Diffusion with Matrigel Experiments. To evaluate HSV-1 virion diffusion through
424 Matrigel, a time-lapse imaging series of virions interacting with the Matrigel interface was
425 performed via inverted laser scanning confocal microscopy (iCLSM) (Stellaris DMI8, Leica).
426 Matrigel (20 μL) was pipetted onto a 35 mm glass-bottom dish (MatTek) and gelled at 37 °C,
427 forming a hemisphere of solid gel on the glass surface. PBS was added to the glass-bottom dish to
428 submerge the Matrigel. The PBS and Matrigel-containing dish was placed on the microscope
429 stage, and a time-lapse imaging series (XYT) was initiated, with the focal point centered on the
430 Matrigel-PBS interface. At $t = 0$ min, 1×10^7 pfu of mRFP-VP26 tagged virions or 1×10^8 of
431 Yellow-Green fluorescent tagged nanoparticles (160 nm, FluoSpheres™ Carboxylate-Modified

432 Microspheres Catalog #F8811, Thermo Fisher Scientific) were added to the dish. Images were
433 acquired at 63x every 10 min for 90 min in two channels: a transmitted light channel (brightfield)
434 and a fluorescence channel (mRFP, FITC).

435 Statistical Analysis

436 *Percentage of YFP Positive Cells.* To quantify the percentage of YFP positive cells, end-
437 point images were analyzed using Fiji ImageJ (44). Cells were found in brightfield. The
438 background intensity of the YFP channel was subtracted from the image, and the percentage of
439 YFP positive cells was quantified. Experiments were repeated in triplicate. Cell counts for Vero
440 cells embedded in microgels ranged from 79 -280 cells/replicate, for Vero cells grown on
441 microgels from 165 - 390 cells/replicate, for Vero cells in suspension from 228 - 456
442 cells/replicate, and for SCG neurons from 84 - 209 cells/replicate. Multiple comparison tests and
443 one-way ANOVAs were performed in Matlab.

444 *The Timing of YFP and RFP Detection.* To quantify the timing of YFP and RFP detection,
445 time-lapse images were analyzed using Fiji ImageJ (44). Cells were difficult to identify in
446 brightfield, so cells were identified by finding YFP positive cells at 16 hpi. Once located, a 30 μ m
447 diameter circular region of interest (ROI) was drawn around each individual cell. The maximum
448 pixel intensity in YFP and RFP for the ROI was then measured for each time-frame. The frame 1
449 maximum pixel intensity of each ROI was subtracted from the subsequent frames for that ROI.
450 The noise threshold was found to be 50 arbitrary units (a.u.) for YFP and 75 a.u. for RFP. The
451 timing of YFP and RFP detection were defined as the first time-frame the YFP and RFP pixel
452 intensities in each ROI were greater than the noise threshold for two consecutive frames. For SCG
453 time-lapse studies, experiments were repeated 3-4 times with a total of 174 cells analyzed. For
454 Vero timelapse studies, experiments were repeated 4 times with a total of 669 cells analyzed.
455 One-way ANOVAs and linear regressions were performed in Matlab.

456
457 **References**

- 459 1. C. Simpson, S. S. Lee, C.-S. Lee, Y. Yamauchi, Microfluidics: an Untapped Resource in
460 Viral Diagnostics and Viral Cell Biology. *Current Clinical Microbiology Reports.* **5**, 245–
461 251 (2018).
- 462 2. N. Drayman, P. Patel, L. Vistain, S. Tay, HSV-1 single-cell analysis reveals the activation of
463 anti-viral and developmental programs in distinct sub-populations. *Elife.* **8** (2019),
464 doi:10.7554/eLife.46339.
- 465 3. W. Liu, H. He, S.-Y. Zheng, Microfluidics in Single-Cell Virology: Technologies and
466 Applications. *Trends Biotechnol.* **38**, 1360–1372 (2020).
- 467 4. A. B. Russell, E. Elshina, J. R. Kowalsky, A. J. W. Te Velthuis, J. D. Bloom, Single-Cell
468 Virus Sequencing of Influenza Infections That Trigger Innate Immunity. *J. Virol.* **93** (2019),
469 doi:10.1128/JVI.00500-19.
- 470 5. A. B. Russell, C. Trapnell, J. D. Bloom, Extreme heterogeneity of influenza virus infection
471 in single cells. *Elife.* **7** (2018), doi:10.7554/eLife.32303.
- 472 6. S. Y. Kupke, L.-H. Ly, S. T. Börno, A. Ruff, B. Timmermann, M. Vingron, S. Haas, U.
473 Reichl, Single-Cell Analysis Uncovers a Vast Diversity in Intracellular Viral Defective
474 Interfering RNA Content Affecting the Large Cell-to-Cell Heterogeneity in Influenza A
475 Virus Replication. *Viruses.* **12** (2020), doi:10.3390/v12010071.

476 7. F. S. Heldt, S. Y. Kupke, S. Dorl, U. Reichl, T. Frensing, Single-cell analysis and stochastic
477 modelling unveil large cell-to-cell variability in influenza A virus infection. *Nat. Commun.* **6**,
478 8938 (2015).

479 8. Y. Zhu, A. Yongky, J. Yin, Growth of an RNA virus in single cells reveals a broad fitness
480 distribution. *Virology*. **385**, 39–46 (2009).

481 9. F. Guo, S. Li, M. U. Caglar, Z. Mao, W. Liu, A. Woodman, J. J. Arnold, C. O. Wilke, T. J.
482 Huang, C. E. Cameron, Single-Cell Virology: On-Chip Investigation of Viral Infection
483 Dynamics. *Cell Rep.* **21**, 1692–1704 (2017).

484 10. A. Timm, J. Yin, Kinetics of virus production from single cells. *Virology*. **424**, 11–17
485 (2012).

486 11. J. Sun, J. C. Vera, J. Drnevich, Y. T. Lin, R. Ke, C. B. Brooke, Single cell heterogeneity in
487 influenza A virus gene expression shapes the innate antiviral response to infection. *PLoS*
488 *Pathog.* **16**, e1008671 (2020).

489 12. A. C. Wilson, Impact of Cultured Neuron Models on α -Herpesvirus Latency Research.
490 *Viruses*. **14** (2022), doi:10.3390/v14061209.

491 13. M. E. Marcocci, G. Napoletani, V. Protto, O. Kolesova, R. Piacentini, D. D. Li Puma, P.
492 Lomonte, C. Grassi, A. T. Palamara, G. De Chiara, Herpes Simplex Virus-1 in the Brain:
493 The Dark Side of a Sneaky Infection. *Trends Microbiol.* **28**, 808–820 (2020).

494 14. J. R. Heath, J. A. Dembowski, Fashionably late: Temporal regulation of HSV-1 late gene
495 transcription. *PLoS Pathog.* **18**, e1010536 (2022).

496 15. B. Roizman, G. Zhou, The 3 facets of regulation of herpes simplex virus gene expression: A
497 critical inquiry. *Virology*. **479–480**, 562–567 (2015).

498 16. H.-L. Hu, K. P. Srinivas, S. Wang, M. V. Chao, T. Lionnet, I. Mohr, A. C. Wilson, D. P.
499 Depledge, T. T. Huang, Single-cell transcriptomics identifies Gadd45b as a regulator of
500 herpesvirus-reactivating neurons. *EMBO Rep.* **23**, e53543 (2022).

501 17. M. K. Pietilä, J. J. Bachmann, J. Ravantti, L. Pelkmans, C. Fraefel, Cellular state landscape
502 and herpes simplex virus type 1 infection progression are connected. *Nat. Commun.* **14**, 4515
503 (2023).

504 18. D. García Alonso, M. Yu, H. Qu, L. Ma, F. Shen, Advances in Microfluidics-Based
505 Technologies for Single Cell Culture. *Adv Biosyst.* **3**, e1900003 (2019).

506 19. A. B. Theberge, F. Courtois, Y. Schaeferli, M. Fischlechner, C. Abell, F. Hollfelder, W. T. S.
507 Huck, Microdroplets in microfluidics: an evolving platform for discoveries in chemistry and
508 biology. *Angew. Chem. Int. Ed Engl.* **49**, 5846–5868 (2010).

509 20. E. K. Loveday, G. K. Zath, D. A. Bikos, Z. J. Jay, C. B. Chang, Screening of Additive
510 Formulations Enables Off-Chip Drop Reverse Transcription Quantitative Polymerase Chain
511 Reaction of Single Influenza A Virus Genomes. *Anal. Chem.* **93**, 4365–4373 (2021).

512 21. E. K. Loveday, H. S. Sanchez, M. M. Thomas, C. B. Chang, Single-Cell Infection of
513 Influenza A Virus Using Drop-Based Microfluidics. *Microbiol Spectr.* **10**, e0099322 (2022).

514 22. A. Rotem, A. W. R. Serohijos, C. B. Chang, J. T. Wolfe, A. E. Fischer, T. S. Mehoke, H.
515 Zhang, Y. Tao, W. Lloyd Ung, J.-M. Choi, J. V. Rodrigues, A. O. Kolawole, S. A. Koehler,
516 S. Wu, P. M. Thielen, N. Cui, P. A. Demirev, N. S. Giacobbi, T. R. Julian, K. Schwab, J. S.
517 Lin, T. J. Smith, J. M. Pipas, C. E. Wobus, A. B. Feldman, D. A. Weitz, E. I. Shakhnovich,
518 Evolution on the Biophysical Fitness Landscape of an RNA Virus. *Mol. Biol. Evol.* **35**,
519 2390–2400 (2018).

520 23. Y. Tao, A. Rotem, H. Zhang, S. K. Cockrell, S. A. Koehler, C. B. Chang, L. W. Ung, P. G.
521 Cantalupo, Y. Ren, J. S. Lin, A. B. Feldman, C. E. Wobus, J. M. Pipas, D. A. Weitz,
522 Artifact-free quantification and sequencing of rare recombinant viruses by using drop-based
523 microfluidics. *Chembiochem.* **16**, 2167–2171 (2015).

524 24. H. Zhang, S. K. Cockrell, A. O. Kolawole, A. Rotem, A. W. R. Serohijos, C. B. Chang, Y.
525 Tao, T. S. Mehoke, Y. Han, J. S. Lin, N. S. Giacobbi, A. B. Feldman, E. Shakhnovich, D. A.
526 Weitz, C. E. Wobus, J. M. Pipas, Isolation and Analysis of Rare Norovirus Recombinants
527 from Coinfected Mice Using Drop-Based Microfluidics. *J. Virol.* **89**, 7722–7734 (2015).

528 25. A. E. Fischer, S. K. Wu, J. B. G. Proescher, A. Rotem, C. B. Chang, H. Zhang, Y. Tao, T. S.
529 Mehoke, P. M. Thielen, A. O. Kolawole, T. J. Smith, C. E. Wobus, D. A. Weitz, J. S. Lin, A.
530 B. Feldman, J. T. Wolfe, A high-throughput drop microfluidic system for virus culture and
531 analysis. *J. Virol. Methods.* **213**, 111–117 (2015).

532 26. Y. Tao, A. Rotem, H. Zhang, C. B. Chang, A. Basu, A. O. Kolawole, S. A. Koehler, Y. Ren,
533 J. S. Lin, J. M. Pipas, A. B. Feldman, C. E. Wobus, D. A. Weitz, Rapid, targeted and culture-
534 free viral infectivity assay in drop-based microfluidics. *Lab Chip.* **15**, 3934–3940 (2015).

535 27. M. Frega, "3D Neuronal Networks: State of the Art" in *Neuronal Network Dynamics in 2D*
536 and *3D in vitro Neuroengineered Systems*, M. Frega, Ed. (Springer International Publishing,
537 Cham, 2016), pp. 45–57.

538 28. A. S. Caldwell, B. A. Aguado, K. S. Anseth, Designing Microgels for Cell Culture and
539 Controlled Assembly of Tissue Microenvironments. *Adv. Funct. Mater.* **30** (2020),
540 doi:10.1002/adfm.201907670.

541 29. Y. Xu, H. Zhu, A. Denduluri, Y. Ou, N. A. Erkamp, R. Qi, Y. Shen, T. P. J. Knowles,
542 Recent Advances in Microgels: From Biomolecules to Functionality. *Small.* **18**, e2200180
543 (2022).

544 30. L. F. Domanico, G. P. Dunn, O. Kobiler, M. P. Taylor, A dual-fluorescent recombinant for
545 live observation of Herpes simplex-type 1 infection outcomes. *bioRxiv* (2023), p.
546 2023.06.07.544108, , doi:10.1101/2023.06.07.544108.

547 31. S. L. Pratt, G. K. Zath, T. Akiyama, K. S. Williamson, M. J. Franklin, C. B. Chang,
548 DropSOAC: Stabilizing Microfluidic Drops for Time-Lapse Quantification of Single-Cell
549 Bacterial Physiology. *Front. Microbiol.* **10**, 2112 (2019).

550 32. C. H. J. Schmitz, A. C. Rowat, S. Köster, D. A. Weitz, Dropspots: a picoliter array in a
551 microfluidic device. *Lab Chip.* **9**, 44–49 (2009).

552 33. E. M. Cohen, O. Kobiler, Gene Expression Correlates with the Number of Herpes Viral
553 Genomes Initiating Infection in Single Cells. *PLoS Pathog.* **12**, e1006082 (2016).

554 34. J. Witten, K. Ribbeck, The particle in the spider's web: transport through biological
555 hydrogels. *Nanoscale*. **9**, 8080–8095 (2017).

556 35. O. Lieleg, K. Ribbeck, Biological hydrogels as selective diffusion barriers. *Trends Cell Biol.*
557 **21**, 543–551 (2011).

558 36. N. Broguiere, L. Isenmann, C. Hirt, T. Ringel, S. Placzek, E. Cavalli, F. Ringnald, L.
559 Villiger, R. Züllig, R. Lehmann, G. Rogler, M. H. Heim, J. Schüler, M. Zenobi-Wong, G.
560 Schwank, Growth of Epithelial Organoids in a Defined Hydrogel. *Adv. Mater.* **30**, e1801621
561 (2018).

562 37. S. Maday, A. E. Twelvetrees, A. J. Moughamian, E. L. F. Holzbaur, Axonal Transport:
563 Cargo-Specific Mechanisms of Motility and Regulation. *Neuron*. **84**, 292–309 (2014).

564 38. W. M. Tierney, I. A. Vicino, S. Y. Sun, W. Chiu, E. A. Engel, M. P. Taylor, I. B. Hogue,
565 Methods and Applications of Campenot Trichamber Neuronal Cultures for the Study of
566 Neuroinvasive Viruses. *Methods Mol. Biol.* **2431**, 181–206 (2022).

567 39. J. Gordon, S. Amini, M. K. White, "General Overview of Neuronal Cell Culture" in
568 *Neuronal Cell Culture: Methods and Protocols*, S. Amini, M. K. White, Eds. (Humana
569 Press, Totowa, NJ, 2013), pp. 1–8.

570 40. K. M. Scherer, J. D. Manton, T. K. Soh, L. Mascheroni, V. Connor, C. M. Crump, C. F.
571 Kaminski, A fluorescent reporter system enables spatiotemporal analysis of host cell
572 modification during herpes simplex virus-1 replication. *J. Biol. Chem.* **296**, 100236 (2021).

573 41. T. H. Ch'ng, E. A. Flood, L. W. Enquist, Culturing primary and transformed neuronal cells
574 for studying pseudorabies virus infection. *Methods Mol. Biol.* **292**, 299–316 (2005).

575 42. J. P. Fredrikson, P. P. Brahmachary, A. E. Erdogan, Z. K. Archambault, J. N. Wilking, R. K.
576 June, C. B. Chang, Metabolomic Profiling and Mechanotransduction of Single Chondrocytes
577 Encapsulated in Alginate Microgels. *Cells*. **11** (2022), doi:10.3390/cells11050900.

578 43. Z. Mahdieh, M. D. Cherne, J. P. Fredrikson, B. Sidar, H. S. Sanchez, C. B. Chang, D.
579 Bimczok, J. N. Wilking, Granular Matrigel: restructuring a trusted extracellular matrix
580 material for improved permeability. *Biomed. Mater.* **17** (2022), doi:10.1088/1748-
581 605X/ac7306.

582 44. C. T. Rueden, J. Schindelin, M. C. Hiner, B. E. DeZonia, A. E. Walter, E. T. Arena, K. W.
583 Eliceiri, ImageJ2: ImageJ for the next generation of scientific image data. *BMC
584 Bioinformatics*. **18**, 529 (2017).

585
586 **Acknowledgments**

587 **Funding:**

588 This work was supported by:

589 National Institutes of Health grant 1R56AI156137-01 (C.B.C.)

590 National Institutes of Health grant R21AI146952-01 (M.P.T.)

591 National Institutes of Health grant R21AI171724-01A1 (M.P.T.)

592 Montana Agricultural Experiment Station HATCH project MONB00029-7004782
593 (M.P.T.)

594 National Science Foundation CAREER grant 1753352 (C.B.C.).

595

596 **Author contributions:**

597 Conceptualization: JPF, LFD, EKL, MPT, and CBC

598 Investigation: JPF, LFD, and SLP

599 Visualization: JPF and LFD

600 Supervision: MPT and CBC

601 Writing—original draft: JPF and LFD

602 Writing—review & editing: JPF, LFD, EKL, MPT, and CBC

603

604 **Competing interests:** The information presented is protected by Provisional Patent
605 application no. 63526916 jointly filed by all authors and Montana State University. All
606 authors declare they have no other competing interests.

607

608 **Data and materials availability:**


609 All data are available in the main text or the supplementary materials. The original
610 imaging files, other data, analysis files, device designs, and reagents are available, upon
611 request, and may be subject to materials transfer agreements (MTAs).

612


613

614


Figures and Tables




615
616
617 **Figure 1 - Experimental schematic for the embedding, growth, and infection of**
618 **individual neurons within microfluidic drops. (A)** SCG neurons are suspended
619 in liquid Matrigel and emulsified in oil. The drops are incubated at 37 °C for 7
620 min for gelation. The microgels and neurons are washed and placed in media for 7
621 days for neuronal maturation. **(B)** After 7 days, the neurons are co-flowed with
622 viral inoculum and emulsified in fluorinated oil. **(C)** A dual-fluorescent HSV-1
623 recombinant is employed to visualize infection. Initiation of viral gene expression
624 is reported by YFP detection. Late gene expression is reported by RFP detection.
625 **(D)** Individual cells can be tracked over time to observe the progression of FP
626 detection.




627
628 **Figure 2 - Impacts of microgels on infection.** (A) Model of Vero cell culture in-
629 microgels, on-microgels, or in-suspension for co-flow inoculation. (B,C,D,E)
630 Representative phase contrast, YFP, and merged images of infected cells. Scale
631 bars are 25 μ m. (B) In-microgels with an internally positioned cell. (C) In-
632 microgels with a peripherally positioned cell. (D) On-microgel. (E) In-suspension.
633 (F) Bar graphs showing the percentage of YFP positive cells. Vero cells cultured
634 as indicated and co-flow inoculated with 10 pfu/drop of dual reporter HSV-1. (G)
635 Bar graphs showing the percentage of YFP positive cells from Vero cells cultured
636 on microgels inoculated with 1, 10, and 100 pfu/drop. This trend was statistically
637 significant (one-way ANOVA, $p = 1.3 \times 10^{-5}$). All infections in F and G were
638 performed in triplicate with an average number of 200 cells per condition per
639 replicate.



640
641 **Figure 3 - HSV-1 virions cannot enter Matrigel. (A)** Representative images of time-
642 lapse confocal microscopy of mRFP labeled HSV-1 virions diffusing next to a disc
643 of Matrigel (right side of image). Images were acquired with a every 10 min for 90
644 min in brightfield and mRFP (false-colored green). **(B)** Nanoparticles (green) were
645 added to the solution surrounding the Matrigel disc. Scale bar = 15 μm , $t = 60$ min.




646
647 **F Figure 4 - Microgels support neuronal maturation and infection. (A)** A
648 representative image of a mature SCG neuron in a Matriigel microgel after 7 days
649 in culture. Cells were stained with Calcein AM, false-colored purple. Scale bar
650 = 25 μ m. **(B)** A mature SCG neuron grown in a microgel immunostained for
651 phosphorylated neuro-filament H (Red) and Nuclei (Blue). Scale bar = 25 μ m. **(C)**
652 Bar graph showing the percentage of YFP positive neurons following infection at
653 1, 10, and 100 pfu/drop. Infections were performed in triplicate with an average of
654 158 cells per replicate per condition. Statistical significance evaluated by one-way
655 ANOVA ($p = 5.9 \times 10^{-4}$). **(D)** Representative phase contrast, YFP, and merged
656 images of an infected SCG neuron. Scale bar = 25 μ m.



657
658 **Figure 5 - The effect of inoculating dose on neuronal infection progression and**
659 **kinetics. (A)** Schematic of experimental design for temporal tracking of YFP and
660 RFP. **(B)** Representative images from time-lapse microscopy of an infected neuron
661 expressing YFP and RFP in a DropSOAC chamber (31). Scale bar = 50 μ m. **(C)**
662 Normalized intensities of YFP (open green squares) and RFP (filled red circles) for
663 the representative cell in (B). Dashed lines represent the threshold value above
664 which cells are considered positive for FP detection. **(D)** Timing of YFP and RFP
665 detection plotted with the mean and standard deviation. Each data point represents
666 quantitation from single neurons. Statistical significance was evaluated by one-
667 way ANOVA ($p = 1.1 \times 10^{-7}$). **(E)** Correlation of YFP versus RFP detection time
668 for RFP positive neurons. (1 pfu/drop - blue X, 10 pfu/drop - purple square, 100
669 pfu/drop - black circle). A linear regression fit to evaluate the significance of
670 correlation is plotted as a dashed line with the fit.

671
672



673
674
675 **Figure 6 - HSV-1 replication kinetics in Vero cells.** (A) Timing of YFP and RFP
676 expression in individual Vero cells plotted with the mean and standard deviation.
677 Timing of YFP detection decreased with increased inoculating dose (one-way
678 ANOVA, $p = 1.9 \times 10^{-35}$). (B) Correlation of YFP versus RFP detection time for
679 RFP positive Vero cells. (1 pfu/drop - blue stars, 10 pfu/drop - purple squares, 100
680 pfu/drop - black circle). (Linear regression: $t_{RFP+} = 6.4 + 0.9x t_{YFP+}$, $p = 1.1 \times 10^{-7}$, $R^2 =$
681 0.22). (C) Representative images of Vero cells infected in drop on microgels.
682 White circles outline the microgel. Scale bar = 50 μ m.

683
684

685 **Supplementary Materials**

686
687 Supplemental Movie 1
688
689
690